Top Story Today
Pfizer Bets $10 Billion on 12 Cancer Drugs From a Chinese Biotech You've Probably Never Heard Of
Pfizer is paying $650 million upfront (and up to $10.5 billion total) for 12 unnamed early-stage cancer programs from Innovent Biologics, a Suzhou-based company that most U.S. investors couldn't pick out of a lineup. The deal spans antibody-drug conjugates and multi-specific antibodies, split into three buckets with varying levels of co-development. It's one of the largest cross-border biopharma collaborations ever, and it lands squarely in the middle of escalating U.S.-China tensions over biotech investment.
Why it matters: With Pfizer staring down patent cliffs and shrinking COVID revenue, this deal reveals how deeply Western pharma depends on Chinese innovation to refill its pipeline, even as Washington moves to restrict those exact relationships.
Read more →Clinical Breakthroughs
The Protein That Mocked Science for 40 Years Just Got Beaten in Pancreatic Cancer
Revolution Medicines' daraxonrasib nearly doubled median survival in previously treated pancreatic cancer patients: 13.2 months versus 6.7 on chemo, a 60% reduction in the risk of death. KRAS, the protein behind over 90% of pancreatic tumors, was considered "undruggable" for four decades. The drug targets active KRAS across multiple mutation types and will be presented in ASCO's most prestigious Plenary Session.
Read more →BMS Hands Protein Degradation Its Biggest Clinical Win Ever
BMS's mezigdomide delivered a statistically significant Phase 3 improvement in progression-free survival for relapsed multiple myeloma, earning a late-breaking oral slot at ASCO 2026. The result is the strongest clinical validation yet for targeted protein degradation, a drug class that destroys disease-causing proteins rather than just blocking them.
Read more →Lilly Brings a New Weapon to Padcev's $3 Billion Bladder Cancer Throne
Eli Lilly unveiled early data at ASCO for a next-gen ADC targeting the same protein as Padcev but carrying a DNA-shredding camptothecin payload instead of Padcev's microtubule disruptor. Preclinical models showed activity in Padcev-resistant cancers. It's Phase 1, so years behind Padcev's blockbuster Phase 3 data, but Lilly earned a coveted oral presentation slot.
Read more →A Shanghai Biotech Just Beat Chemo in First-Line Lung Cancer
Dizal Pharma's sunvozertinib, an oral pill targeting EGFR exon 20 insertions, hit its primary endpoint in first-line lung cancer. That's a direct challenge to incumbents in a growing market. Full results drop at ASCO as a late-breaking oral, and the geopolitical timing couldn't be more charged.
Read more →Deals and M&A
A $7 Billion Napkin Could Reshape Nuclear Medicine
PE-backed Curium Pharma has offered roughly $7 billion for Lantheus Holdings, the company behind prostate cancer imaging agent Pylarify. Lantheus is actively exploring a sale. Combining Curium's European dominance with Lantheus's U.S. franchise would create a global radiopharmaceutical giant, though Pylarify faces growing pricing pressure from cheaper competitors.
Read more →Gilead Paid $405 Million for MiroBio—and Has Little to Show for It
Gilead's $405 million MiroBio acquisition has yet to yield a clear clinical winner, adding to a growing pattern of expensive M&A misses that includes the $4.9 billion Forty Seven deal. With $11.5 billion in new deal charges booked this year, investors are questioning whether Gilead is getting worse at shopping.
Read more →Policy and Industry
Congress Wants to Add Biotech to China Investment Restrictions. Pharma's Sweating.
House leaders are pushing Treasury to add biotechnology to the COINS Act, which already restricts U.S. investment in Chinese AI and semiconductors. The kicker: a growing share of large-cap pharma's major licensing deals now involve Chinese companies. Lawmakers want to scrutinize not just equity investments but licensing deals, drug discovery platforms, and manufacturing partnerships.
Read more →Big Pharma Has Pledged $350 Billion in U.S. Drug Factories. Don't Pop the Champagne Yet.
Facing 100% tariffs on imported drugs, biopharma companies have pledged over $350 billion for U.S. manufacturing since January. The catch: new pharma plants take five to ten years to build, the talent pool is razor thin, and analysts suspect some pledges simply repackage projects that were already planned.
Read more →ICON's 1% Revenue Error Cost Investors $5 Billion in a Single Day
ICON plc's accounting probe found revenue was overstated by less than 2%, but shares had already cratered 49% when the investigation was first disclosed. The episode is a reminder that in the clinical trials business, even small credibility gaps carry enormous costs.
Read more →